This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis
by Zacks Equity Research
Biogen (BIIB) obtains a license to develop and commercialize BIIB067 from Ionis Pharmaceuticals. The candidate is being developed for treatment of ALS with SOD1 mutations.
Inovio (INO) to Receive Milestone Payment From AstraZeneca
by Zacks Equity Research
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
UNITY (UBX) Soars: Stock Adds 5.1% in Session
by Zacks Equity Research
UNITY (UBX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Should You Get Rid of Acadia Healthcare (ACHC) Now?
by Zacks Equity Research
Acadia Healthcare (ACHC) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Amgen's BiTE Immunotherapies Show Promise in Early Studies
by Zacks Equity Research
Amgen's (AMGN) BiTE immunotherapy candidates, namely AMG 420 and AMG 330 show positive results in early-stage studies. AMG 420 gets a fast track designation from the FDA
Global Blood Therapeutics' Voxelotor on Faster Approval Path
by Zacks Equity Research
Global Blood Therapeutics (GBT) announces FDA nod for an accelerated approval pathway for voxelotor as a treatment for sickle cell disease. Stock rallies.
FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate
by Zacks Equity Research
The FDA's BRUDAC committee will review Amgen (AMGN) and its European partner UCB's BLA for Evenity so that the candidate gets approved for treating osteoporosis in postmenopausal women.
Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%
by Zacks Equity Research
Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Why Immunomedics (IMMU) Could Be Positioned for a Slump
by Zacks Equity Research
Immunomedics (IMMU) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Aileron Inks Collaboration Deal With Pfizer for Cancer Combo
by Zacks Equity Research
Aileron Therapeutics (ALRN) signs a clinical trial collaboration contract with Pfizer to study the combo of Aileron's ALRN-6924 and Pfizer's Ibrance for treating MDM2-amplified cancers. Stock rises.
Eyenovia Initiates Phase III Study for Mydriasis Candidate
by Zacks Equity Research
Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies.
Rocket Pharmaceuticals (RCKT) in Focus: Stock Moves 7.2% Higher
by Zacks Equity Research
Rocket Pharmaceuticals (RCKT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Keryx (KERX) Looks Good: Stock Adds 7.2% in Session
by Zacks Equity Research
Keryx (KERX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint
by Zacks Equity Research
Emergent BioSolutions (EBS) and partner Valneva present positive data from an early-stage study on the Zika vaccine candidate, VLA1601.
Fortress Biotech (FBIO) in Focus: Stock Moves 6.5% Higher
by Zacks Equity Research
Fortress Biotech (FBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Amgen's Blincyto Gets Positive CHMP Opinion for Line Extension
by Zacks Equity Research
Amgen's (AMGN) leukemia drug, Blincyto receives positive CHMP opinion for label expansion to include minimal residual disease.
Seattle Genetics (SGEN) Looks Good: Stock Adds 5.6% in Session
by Zacks Equity Research
Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 6% on Friday, amid huge volumes.
Biotech Stock Outlook: Approval of New Drugs to Boost Performance
by Zacks Equity Research
While decline in sales of high-profile drugs and competitive pressure are likely to weigh on the biotech sector, we expect approval of new drugs to offset the impact of the same.
Acorda Down More Than 30% in the Past 3 Months: Here's Why
by Zacks Equity Research
Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States while its lead Parkinson disease candidate Inbrija's review timeline gets extended by three months.
Looking for a Growth Stock? Why It is Time to Focus on Alexion Pharmaceuticals (ALXN)
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Amarin's Vascepa Cuts Heart Risk in Outcomes Test, Stock Down
by Zacks Equity Research
Amarin (AMRN) posts detailed data from a late-stage cardiovascular outcomes study on its fish oil drug Vascepa. The stock takes a hit.
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.
Medicines Company (MDCO) Q3 Loss Widens, Inclisiran in Focus
by Zacks Equity Research
The Medicines Company (MDCO) suffers a wider-than-expected loss in Q3. At the same time, the company posts negative revenues.
Arena Pharmaceuticals (ARNA) Beats on Q3 Earnings and Sales
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) betters loss estimates in Q3. Also, the top line surpasses the consensus mark.
PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings trump estimates in Q3. Higher royalties and product sales aid a significant surge in year-over-year revenues.